Literature DB >> 16806202

Mouse adenovirus type 1 attachment is not mediated by the coxsackie-adenovirus receptor.

L Lenaerts1, D Daelemans, N Geukens, E De Clercq, L Naesens.   

Abstract

Common human adenovirus (Ad) vectors are derived from serotype 2 or 5, which use the coxsackie-adenovirus receptor (CAR) as their primary cell receptor. We investigated the receptor usage of mouse adenovirus type 1 (MAV-1), which in vivo is characterized by a pronounced endothelial cell tropism. Alignment of the fiber knob sequences of MAV-1 and those of CAR-using adenoviruses, revealed that amino acid residues, critical for interaction with CAR, are not conserved in the MAV-1 fiber knob. Attachment of MAV-1 to Chinese hamster ovary (CHO) cells was not increased by stable transfection with mouse CAR, whereas the binding efficiency of Ad2 was 20-fold higher in the mouse CAR-transfectant compared to the wild type cells. Also, purified fiber knob of Ad5, which is interchangeable with the Ad2 fiber knob, did not compete with MAV-1 for receptor binding, indicating that MAV-1 binds to a receptor different from CAR. These results support further exploration of an MAV-1-derived vector as a potential vehicle for gene delivery to cell types which are not efficiently transduced by human adenovirus vectors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806202     DOI: 10.1016/j.febslet.2006.06.027

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Effects of allergic airway disease on mouse adenovirus type 1 respiratory infection.

Authors:  Victoria E Anderson; Yn Nguyen; Jason B Weinberg
Journal:  Virology       Date:  2009-06-28       Impact factor: 3.616

2.  1. Alternative splicing of viral receptors: A review of the diverse morphologies and physiologies of adenoviral receptors.

Authors:  Katherine J D A Excoffon; Jonathan R Bowers; Priyanka Sharma
Journal:  Recent Res Dev Virol       Date:  2014

Review 3.  Murine adenoviruses: tools for studying adenovirus pathogenesis in a natural host.

Authors:  Silvio Hemmi; Katherine R Spindler
Journal:  FEBS Lett       Date:  2019-12-06       Impact factor: 4.124

4.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

5.  Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis.

Authors:  Yn Nguyen; Bryan A McGuffie; Victoria E Anderson; Jason B Weinberg
Journal:  Virology       Date:  2008-09-02       Impact factor: 3.616

Review 6.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

7.  Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection.

Authors:  L Lenaerts; H Kelchtermans; L Geboes; P Matthys; E Verbeken; E De Clercq; L Naesens
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

8.  Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.

Authors:  Michael Robinson; Betty Li; Ying Ge; Derek Ko; Satya Yendluri; Thomas Harding; Melinda VanRoey; Katherine R Spindler; Karin Jooss
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

9.  Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans.

Authors:  Liesbeth Lenaerts; Wim van Dam; Leentje Persoons; Lieve Naesens
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

10.  The RGD-binding integrins αvβ6 and αvβ8 are receptors for mouse adenovirus-1 and -3 infection.

Authors:  Manuela Bieri; Rodinde Hendrickx; Michael Bauer; Bin Yu; Tania Jetzer; Birgit Dreier; Peer R E Mittl; Jens Sobek; Andreas Plückthun; Urs F Greber; Silvio Hemmi
Journal:  PLoS Pathog       Date:  2021-12-15       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.